Division of Hematology and Oncology Archives
Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments
May. 11, 2023—The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.
Vanderbilt mourns loss of former Hematology leader Krantz
Apr. 18, 2023—Sanford Krantz, MD, internationally recognized authority on hematology and erythropoietin and professor of Medicine, Emeritus, died April 13 at his home. He was 89.
National Cancer Institute honors Berlin’s contributions, leadership
Apr. 6, 2023—Vanderbilt's Jordan Berlin, MD, is a 2022 recipient of the National Cancer Institute Director’s Award.
New treatment helps mitigate hair loss for chemotherapy patients
Mar. 30, 2023—Vanderbilt-Ingram Cancer Center has started offering scalp cooling, which mitigates hair loss for patients receiving certain chemotherapy regimens.
Study evaluates polygenic risk score for prostate cancer risk prediction
Mar. 16, 2023—A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.
Targeted therapy for neuroendocrine tumors
Feb. 16, 2023—Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.
Berlin named director of Division of Hematology and Oncology
Feb. 6, 2023—Jordan Berlin, MD, has been named director of Vanderbilt’s Division of Hematology and Oncology.
New Clinician Spotlight: Muhamed Baljević
Sep. 29, 2022—Specializing in myeloma, amyloidosis and other plasma cell disorders, hematologist and medical oncologist Muhamed Baljević, MD, recently joined Vanderbilt University Medical Center.
Policy, resources crucial for lung cancer screening: study
Sep. 29, 2022—Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened.
Blood cancer progression
Aug. 29, 2022—Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
Cell-free breast cancer “biopsy”
Aug. 11, 2022—The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
